In support of this, PDGF-DD is abundantly expressed in GBM, suggesting a novel mode of NK cell tumor surveillance (50), but the clinical significance of the NKp44-PDGF-DD pathway for anti-tumor immunity in many other human cancers including LGG remains unclear. Here, NCR2 is linked to neoplasm.